Francisco Pérez-Cózar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francisco Pérez-Cózar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Concepción Marañón
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avda. de la Ilustración 114, Granada 18016, Spain
2 shared publications - Aida Fiz-López
Mucosal Immunology Laboratory, Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Sanz y Forés 3, Valladolid 47003, Spain
1 shared publication - Antonio García-Blesa
Mucosal Immunology Laboratory, Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Sanz y Forés 3, Valladolid 47003, Spain
1 shared publication - Antonio Orduña
Microbiology Unit, Hospital Clínico Universitario de Valladolid, Avda. Ramón y Cajal 3, Valladolid 47003, Spain
1 shared publication - Carlos Dueñas
Hospital Clínico de Valladolid Valladolid Spain
1 shared publication - Carolina G. de Castro
Mucosal Immunology Laboratory, Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Sanz y Forés 3, Valladolid 47003, Spain
1 shared publication
Latest Publications
- Open Access
- 17 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106731
Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID
- 17 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106731
Open AccessPersistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID
- Open Access
- 1 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7143
Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis
The kidney is one of the main organs affected by the autoimmune disease systemic lupus erythematosus. Lupus nephritis (LN) concerns 30–60% of adult SLE patients and it is significantly associated with an increase in the morbidity and mortality. The definitive diagnosis of LN can only be achieved by histological analysis of renal biopsies, but the invasiveness of this technique is an obstacle for early diagnosis of renal involvement and a proper follow-up of LN patients under treatment. The use of urine for the discovery of non-invasive biomarkers for renal disease in SLE patients is an attractive alternative to repeated renal biopsies, as several studies have described surrogate urinary cells or analytes reflecting the inflammatory state of the kidney, and/or the severity of the disease. Herein, we review the main findings in the field of urine immune-related biomarkers for LN patients, and discuss their prognostic and diagnostic value. This manuscript is focused on the complement system, antibodies and autoantibodies, chemokines, cytokines, and leukocytes, as they are the main effectors of LN pathogenesis.
- 1 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7143
Open AccessImmune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis
The kidney is one of the main organs affected by the autoimmune disease systemic lupus erythematosus. Lupus nephritis (LN) concerns 30–60% of adult SLE patients and it is significantly associated with an increase in the morbidity and mortality. The definitive diagnosis of LN can only be achieved by histological analysis of renal biopsies, but the invasiveness of this technique is an obstacle for early diagnosis of renal involvement and a proper follow-up of LN patients under treatment. The use of urine for the discovery of non-invasive biomarkers for renal disease in SLE patients is an attractive alternative to repeated renal biopsies, as several studies have described surrogate urinary cells or analytes reflecting the inflammatory state of the kidney, and/or the severity of the disease. Herein, we review the main findings in the field of urine immune-related biomarkers for LN patients, and discuss their prognostic and diagnostic value. This manuscript is focused on the complement system, antibodies and autoantibodies, chemokines, cytokines, and leukocytes, as they are the main effectors of LN pathogenesis.